Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy in those with type 2 diabetes.

After stopping Ozempic, many struggle to maintain weight loss due to hormonal changes, behavioral factors, and a slowed ...

The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...

The former Big Brother contestant turned to the controversial weight loss jab after gaining two stone in weight following the ...

A new study shows that GLP-1 drugs offer health benefits such as reducing risks for heart disease but also carry potential risks like gastrointestinal issues.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...

Topiramate, primarily used for epilepsy and migraine prevention, is emerging as a cost-effective treatment for weight loss ...